TuisOGN • NYSE
add
Organon & Co
Vorige sluiting
$8,94
Dagwisseling
$8,87 - $9,06
Jaarwisseling
$8,01 - $19,05
Markkapitalisasie
2,35 mjd USD
Gemiddelde volume
3,65 m
P/V-verhouding
3,36
Dividend-opbrengs
0,88%
Primêre beurs
NYSE
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,59 mjd | -0,81% |
Bedryfskoste | 548,00 m | -0,90% |
Netto inkomste | 145,00 m | -25,64% |
Netto winsgrens | 9,10 | -24,98% |
Wins per aandeel | 1,00 | -10,71% |
EBITDA | 425,00 m | -5,97% |
Effektiewe belastingkoers | 36,68% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 599,00 m | -14,91% |
Totale bates | 13,50 mjd | 11,07% |
Totale aanspreeklikheid | 12,77 mjd | 6,30% |
Totale ekwiteit | 733,00 m | — |
Uitstaande aandele | 259,97 m | — |
Prys om te bespreek | 3,17 | — |
Opbrengs op bates | 6,30% | — |
Opbrengs op kapitaal | 8,78% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 145,00 m | -25,64% |
Kontant van bedrywe | 220,00 m | -33,73% |
Kontant van beleggings | -38,00 m | 17,39% |
Kontant van finansiering | -223,00 m | -66,42% |
Netto kontantverandering | 52,00 m | -59,69% |
Beskikbare kontantvloei | 91,12 m | -60,79% |
Meer oor
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Wikipedia
Gestig
1923
Webwerf
Werknemers
10 000
